Hsbc Holdings PLC Has $8.25 Million Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Hsbc Holdings PLC decreased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 8.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 228,030 shares of the specialty pharmaceutical company’s stock after selling 22,334 shares during the period. Hsbc Holdings PLC’s holdings in Supernus Pharmaceuticals were worth $8,246,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC grew its holdings in Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 870 shares during the period. Mark Sheptoff Financial Planning LLC bought a new position in Supernus Pharmaceuticals during the fourth quarter worth about $52,000. Headlands Technologies LLC grew its holdings in Supernus Pharmaceuticals by 203.0% during the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 1,015 shares during the period. Newbridge Financial Services Group Inc. bought a new position in Supernus Pharmaceuticals during the fourth quarter worth about $72,000. Finally, Venturi Wealth Management LLC bought a new position in Supernus Pharmaceuticals during the fourth quarter worth about $92,000.

Insider Activity at Supernus Pharmaceuticals

In related news, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the sale, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on SUPN. Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 17th.

Supernus Pharmaceuticals Trading Up 0.1 %

Shares of SUPN stock opened at $32.25 on Tuesday. The stock has a market cap of $1.80 billion, a P/E ratio of 30.14 and a beta of 0.90. The stock has a 50 day simple moving average of $31.92 and a 200 day simple moving average of $35.01. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.